Vismodegib(879085-55-9)

Overview: Vismodegib, trade name: Erivedge; It is one of the first new anti-tumor drugs applied by Genentech Co., Ltd. and approved by the US Food and Drug Administration (FDA) for the treatment of advanced skin basal cell carcinoma (BCC) on January 30, 2012.

Purpose: It is used for the treatment of locally progressive or metastatic basal cell carcinoma in adults with recurrent or discomfort after surgery or radiotherapy; Basal cell carcinoma (BCC) is one of the most common skin cancers. It originates from the surface of the skin, and the patient will not feel pain. For skin diseases that are often exposed to sunlight or ultraviolet radiation, the probability of occurrence is the highest. The R&D and listing of Vimodge has brought good news to BCC patients. Its clinical role is important and its target market is huge. It will grow into a "giant bomb" drug (>US $1 billion) in the future.

PREVIOUS：4-Chloro-3-(trifluoromethyl)phenyl isocyanate NEXT：Exemestane(107868-30-4)